{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T08:29:08Z","timestamp":1778315348128,"version":"3.51.4"},"reference-count":32,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T00:00:00Z","timestamp":1721433600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: The objective of this study was to evaluate, the clinical benefit of benralizumab in patients with uncontrolled severe asthma associated with chronic rhinosinusitis with nasal polyposis (CRSwNP). Methods: The study included patients with uncontrolled severe asthma associated with CRSwNP who started therapy with benralizumab. Pulmonary function, eosinophilia, IgE, comorbidity, changes in the Asthma Control Test (ACT), Asthma Control Questionnaire (ACQ), Visual Analogue Scale (VAS), Quality of Life (AQLQ), VAS (obstruction, drip, anosmia, facial pressure), SNOT-22, decrease or withdrawal of steroids and other medication, hospital admissions and emergency visits were analysed. The FEOS scale and EXACTO were employed in the assessment of response. Results: We analyzed 58 patients who completed minimal treatment at 12 months. After treatment with benralizumab, exacerbations were reduced by 82% (p &lt; 0.001), steroid cycles by 84% (p &lt; 0.001), emergencies visit by 83% p &lt; 0.001) and admissions by 76% (p &lt; 0.001), improving all the scales for asthma control, (p &lt; 0.001). In terms of lung function, differences were observed in FVC% (p &lt; 0.001), FEV1% (p &lt; 0.001), and FEV1\/FVC% (69.5 \u00b1 10 vs. 74 \u00b1 10, p &lt; 0.001). In relation to CRSwNP, differences were observed in SNOT-22 (54.66 \u00b1 17 vs. 20.24 \u00b1 9, p &lt; 0.001), VAS obstruction (7.91 \u00b1 1 vs. 1.36 \u00b1 1, p &lt; 0. 001), VAS drip (7.76 \u00b1 1 vs. 1.38 \u00b1 1, p &lt; 0.001), VAS anosmia (7.66 \u00b1 1 vs. 1.38 \u00b1 1, p &lt; 0.001) and VAS facial pressure (7.91 \u00b1 1 vs. 1.22 \u00b1 1, p &lt; 0.001). The mean FEOS score after treatment was 73 \u00b1 14. A complete response\/super response was achieved in 33 patients (57%), good response in 16 (28%) and partial response in 9 (15%). Conclusions: The administration of benralizumab to patients with uncontrolled severe asthma associated with CRSwNP has been demonstrated to improve nasal symptoms, asthma control and lung function. This resulted in a reduction in the need for oral steroids, maintenance and rescue medication, emergency room visits, and hospital admissions, with 57% of patients achieving the clinical remission criteria.<\/jats:p>","DOI":"10.3390\/jcm13144247","type":"journal-article","created":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T14:45:53Z","timestamp":1721659553000},"page":"4247","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Real-Life Clinical Outcomes of Benralizumab Treatment in Patients with Uncontrolled Severe Asthma and Coexisting Chronic Rhinosinusitis with Nasal Polyposis"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3374-4623","authenticated-orcid":false,"given":"Eusebi","family":"Chiner","sequence":"first","affiliation":[{"name":"Pulmonology Department, University Hospital of Saint John of Alicante, 03550 Alicante, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Murcia","sequence":"additional","affiliation":[{"name":"Pulmonology Department, University Hospital of Saint John of Alicante, 03550 Alicante, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8225-3623","authenticated-orcid":false,"given":"Ignacio","family":"Boira","sequence":"additional","affiliation":[{"name":"Pulmonology Department, University Hospital of Saint John of Alicante, 03550 Alicante, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0984-1888","authenticated-orcid":false,"given":"Mar\u00eda \u00c1ngeles","family":"Bernabeu","sequence":"additional","affiliation":[{"name":"Pharmacy Department, University Hospital of Saint John of Alicante, 03550 Alicante, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3836-5884","authenticated-orcid":false,"given":"Violeta","family":"Esteban","sequence":"additional","affiliation":[{"name":"Pulmonology Department, University Hospital of Saint John of Alicante, 03550 Alicante, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8986-9463","authenticated-orcid":false,"given":"Eva","family":"Mart\u00ednez-Morag\u00f3n","sequence":"additional","affiliation":[{"name":"Pulmonology Department, Doctor Peset University Hospital, 46017 Valencia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,7,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"100277","DOI":"10.1016\/j.opresp.2023.100277","article-title":"GEMA 5.3. Spanish Guideline on the Management of Asthma","volume":"5","author":"Plaza","year":"2023","journal-title":"Open Respir. Arch."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/all.14902","article-title":"Benralizumab improves symptoms of patients with severe, eosinophilic asthma with a diagnosis of nasal polyposis","volume":"77","author":"Canonica","year":"2022","journal-title":"Allergy"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"100606","DOI":"10.1016\/j.waojou.2021.100606","article-title":"Severe asthma: One disease and multiple definitions","volume":"14","author":"Bagnasco","year":"2021","journal-title":"World Allergy Organ. J."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/j.1398-9995.2005.00725.x","article-title":"Nasal polyposis and its impact on quality of life: Comparison between the effects of medical and surgical treatments","volume":"60","author":"Alobid","year":"2005","journal-title":"Allergy"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1002\/pro.2072","article-title":"Structural basis of interleukin-5 dimer recognition by its \u03b1 receptor","volume":"21","author":"Kusano","year":"2012","journal-title":"Protein Sci."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1164\/rccm.201810-1944CI","article-title":"Role of Biologics in Asthma","volume":"199","author":"McGregor","year":"2019","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1111\/all.14221","article-title":"Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines\u2014Recommendations on the use of biologicals in severe asthma","volume":"75","author":"Agache","year":"2020","journal-title":"Allergy"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"84","DOI":"10.18176\/jiaci.0385","article-title":"Benralizumab: A New Approach for the Treatment of Severe Eosinophilic Asthma","volume":"29","author":"Moreno","year":"2019","journal-title":"J. Investig. Allergol. Clin. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"00383","DOI":"10.1183\/23120541.00383-2023","article-title":"Benralizumab in severe eosinophilic asthma in real life: Confirmed effectiveness and contrasted effect on sputum eosinophilia versus exhaled nitric oxide fraction\u2014PROMISE","volume":"9","author":"Schleich","year":"2023","journal-title":"ERJ Open Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"419","DOI":"10.18176\/jiaci.0939","article-title":"Improvement in Smell Using Monoclonal Antibodies Among Patients With Chronic Rhinosinusitis With Nasal Polyps: A Systematic Review","volume":"33","author":"Barroso","year":"2023","journal-title":"J. Investig. Allergol. Clin. Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1111\/cea.13852","article-title":"Benralizumab effect on severe chronic rhinosinusitis with nasal polyps (CRSwNP): A randomized double-blind placebo-controlled trial","volume":"51","author":"Tversky","year":"2021","journal-title":"Clin. Exp. Allergy"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"101965","DOI":"10.1016\/j.pupt.2020.101965","article-title":"Rapid effect of benralizumab for severe asthma with chronic rhinosinusitis with nasal polyps","volume":"64","author":"Matsuno","year":"2020","journal-title":"Pulm. Pharmacol. Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","article-title":"Benralizumab, an anti-interleukin-5 receptor \u03b1 monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): A randomised, double-blind, placebo-controlled phase 3 trial","volume":"388","author":"FitzGerald","year":"2016","journal-title":"Lancet"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.jaci.2021.08.030","article-title":"Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: A randomized, placebo-controlled trial","volume":"149","author":"Bachert","year":"2022","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S2213-2600(20)30414-8","article-title":"Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): A randomised, controlled, phase 3b trial","volume":"9","author":"Harrison","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"317","DOI":"10.18176\/jiaci.0910","article-title":"Spanish Consensus on the Management of Chronic Rhinosinusitis With Nasal Polyps (POLIposis NAsal\/POLINA 2.0)","volume":"33","author":"Alobid","year":"2023","journal-title":"J. Investig. Allergol. Clin. Immunol."},{"key":"ref_17","first-page":"388","article-title":"Spirometry","volume":"9","author":"Calle","year":"2013","journal-title":"Arch. Bronconeumol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.jaci.2012.08.023","article-title":"The Asthma Control Test and Asthma Control Questionnaire for assessing asthma control: Systematic review and meta-analysis","volume":"131","author":"Jia","year":"2013","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/alr.22888","article-title":"The predictive utility of the 22-item sino-nasal outcome test (SNOT-22): A scoping review","volume":"12","author":"Liu","year":"2022","journal-title":"Int. Forum Allergy Rhinol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1016\/j.jaip.2021.01.033","article-title":"Development of a Tool to Measure the Clinical Response to Biologic Therapy in Uncontrolled Severe Asthma: The FEV1, Exacerbations, Oral Corticosteroids, Symptoms Score","volume":"9","author":"Almonacid","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_21","first-page":"100192","article-title":"Documento de consenso de asma grave en adultos. Actualizaci\u00f3n 2022 [Consensus document for severe asthma in adults. 2022 update]","volume":"4","author":"Plaza","year":"2022","journal-title":"Open Respir Arch."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"D\u2019Amato, M., Menzella, F., Altieri, E., Bargagli, E., Bracciale, P., Brussino, L., Caiaffa, M.F., Canonica, G.W., Caruso, C., and Centanni, S. (2022). Benralizumab in Patients With Severe Eosinophilic Asthma With and Without Chronic Rhinosinusitis With Nasal Polyps: An ANANKE Study post-hoc Analysis. Front. Allergy., 3.","DOI":"10.3389\/falgy.2022.881218"},{"key":"ref_23","first-page":"1","article-title":"Real-world clinical remission of severe asthma with benralizumab in Spanish adults with severe asthma","volume":"4","author":"Chiner","year":"2024","journal-title":"J. Asthma."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.arbres.2023.11.011","article-title":"Comparison of Long-term Response and Remission to Omalizumab and Anti-IL-5\/IL-5R Using Different Criteria in a Real-life Cohort of Severe Asthma Patients","volume":"60","author":"Betancor","year":"2024","journal-title":"Arch. Bronconeumol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1186\/s12931-023-02539-7","article-title":"Achieving clinical outcomes with benralizumab in severe eosinophilic asthma patients in a real-world setting: Orbe II study","volume":"24","year":"2023","journal-title":"Respir. Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","article-title":"Oral Glucocorticoid- Sparing Effect of Benralizumab in Severe Asthma","volume":"376","author":"Nair","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"106080","DOI":"10.1016\/j.rmed.2020.106080","article-title":"Efficacy of Benralizumab in severe asthma in real life and focus on nasal polyposis","volume":"171","author":"Bagnasco","year":"2020","journal-title":"Respir. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2058738420950851","DOI":"10.1177\/2058738420950851","article-title":"Real-life effects of benralizumab on allergic chronic rhinosinusitis and nasal polyposis associated with severe asthma","volume":"34","author":"Lombardo","year":"2020","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"4371","DOI":"10.1016\/j.jaip.2021.08.004","article-title":"Benralizumab Effectiveness in Severe Eosinophilic Asthma with and without Chronic Rhinosinusitis with Nasal Polyps: A Real-World Multicenter Study","volume":"9","author":"Nolasco","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Pini, L., Bagnasco, D., Begh\u00e8, B., Braido, F., Cameli, P., Caminati, M., Caruso, C., Crimi, C., Guarnieri, G., and Latorre, M. (2024). Unlocking the Long-Term Effectiveness of Benralizumab in Severe Eosinophilic Asthma: A Three-Year Real-Life Study. J. Clin. Med., 13.","DOI":"10.20944\/preprints202402.1390.v1"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting \u03b22-agonists (SIROCCO): A randomised, multicentre, placebo-controlled phase 3 trial","volume":"388","author":"Bleecker","year":"2016","journal-title":"Lancet"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1080\/02770903.2022.2139718","article-title":"Cost-effectiveness of benralizumab versus mepolizumab and dupilumab in patients with severe uncontrolled eosinophilic asthma in Spain","volume":"60","author":"Mareque","year":"2023","journal-title":"J. Asthma."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/14\/4247\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:20:24Z","timestamp":1760109624000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/14\/4247"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,20]]},"references-count":32,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2024,7]]}},"alternative-id":["jcm13144247"],"URL":"https:\/\/doi.org\/10.3390\/jcm13144247","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,20]]}}}